Inovio shares slide after FDA hits it with a hold on lead PhIII HPV program
The FDA has placed Inovio’s lead therapy on clinical hold, halting any new work on the program and putting off a planned start to the Phase III work.
The hold freezes efforts on VGX-3100 as the agency looks for “additional data to support the shelf-life of the newly designed and manufactured disposable parts of the Cellectra 5PSP immunotherapy delivery device,” says the biotech $INO.
Inovio said in a brief statement that it now expects to launch the Phase III work in the first half of 2017. Its shares dropped 16% on the news.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.